Cantor Fitzgerald Reiterates Neutral on Karuna Therapeutics, Maintains $214 Price Target
Portfolio Pulse from richadhand@benzinga.com
Cantor Fitzgerald analyst Charles Duncan has reiterated a Neutral rating on Karuna Therapeutics (NASDAQ:KRTX) and maintained a price target of $214.
August 22, 2023 | 1:53 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Karuna Therapeutics' stock rating has been reiterated as Neutral by Cantor Fitzgerald, with a maintained price target of $214.
The reiteration of a Neutral rating indicates that the analyst sees the stock as fairly valued at current levels. The maintained price target of $214 suggests that the analyst does not expect significant price movement in the short term. This could lead to a neutral impact on the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100